Live Analyst Rating Changes 7757 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Patrick Dolezal
LIFE
Patrick Dolezal
LifeSci Capital
Wall Street Analyst
★★☆☆☆
#2283
on 13Foresight · ranked by our own returns
50%
Success Rate
+25.6%
Average Return
9 of 18 calls profitable · +10.0% vs benchmark
📈 Across the calls we could measure, roughly 50% of Patrick Dolezal's ratings turned a profit when each position was held for 1 year — averaging +25.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

72 Buy 0 Hold 0 Sell
Patrick's Stock Coverage 17 ratings · 2026-07-10
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
NGNE
Neurogene
 Jul 07, 2026 BUY Strong Buy
+19.6% avg upside
23 analysts
$65.00
51.65% Upside
 ·
IBIO
Ibio
 Jul 01, 2026 BUY Strong Buy
+283.1% avg upside
11 analysts
$5.00
231.09% Upside
 ·
KOD
Kodiak Sciences
 Jun 29, 2026 BUY Buy
+23.1% avg upside
11 analysts
$65.00
62.22% Upside
 +6.8%
MBX
MBX Biosciences, Inc.
 Jun 18, 2026 BUY Strong Buy
+1.8% avg upside
14 analysts
$91.00
38.58% Upside
 +34.1%
IMMX
Immix Biopharma
 Jun 17, 2026 BUY Strong Buy
+61.2% avg upside
8 analysts
$19.00
71.35% Upside
 ·
OCS
Oculis Holding
 Jun 06, 2026 BUY Strong Buy
+180.4% avg upside
11 analysts
$45.00
228.47% Upside
 +29.7%
SLGL
Sol-Gel Technologies
 May 28, 2026 BUY Strong Buy
+54.1% avg upside
6 analysts
$184.00
140.96% Upside
 ·
SRZN
Surrozen
 May 09, 2026 BUY Sell
+48.3% avg upside
7 analysts
$44.00
87.29% Upside
 -19.7%
RCKT
Rocket Pharmaceuticals
 May 09, 2026 BUY Buy
+293.4% avg upside
29 analysts
$12.00
186.38% Upside
 -17.5%
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 May 09, 2026 BUY Strong Buy
+88.2% avg upside
17 analysts
$104.00
88.66% Upside
 +43.9%
TARS
Tarsus Pharmaceuticals
 Dec 11, 2023 BUY Strong Buy
+17.9% avg upside
16 analysts
$60.00
6.45% Downside
 +193.1%
VYNE
VYNE Therapeutics
 Nov 11, 2023 BUY Strong Buy
+1909.0% avg upside
9 analysts
$6.00
792.92% Upside
 -13.2%
LRMR
Larimar Therapeutics
 Aug 10, 2023 BUY Strong Buy
+343.7% avg upside
22 analysts
$14.00
238.91% Upside
 +101.6%
TNYA
Tenaya Therapeutics
 Mar 09, 2023 BUY Strong Buy
+1067.5% avg upside
11 analysts
$16.00
1782.32% Upside
 +119.2%
CLDX
Celldex
 Dec 11, 2022 BUY Strong Buy
+0.2% avg upside
28 analysts
$39.00
0.01% Upside
 -19.8%
IVA
Inventiva
 Mar 08, 2021 BUY Strong Buy
+257.3% avg upside
16 analysts
$25.00
451.91% Upside
 -18.3%
FR:IVA
Inventiva
 Jun 16, 2020 BUY Strong Buy
+367.8% avg upside
5 analysts
$25.00
551.06% Upside
 ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Patrick Dolezal — Frequently Asked Questions
How accurate are Patrick Dolezal's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Patrick's ratings were profitable over a one-year hold, with an average return of +22.9% per rating, or +7.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Patrick ranked on 13Foresight?
Patrick Dolezal is currently ranked #2283 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Patrick cover?
Patrick most recently has ratings on NGNE, IBIO, KOD, MBX, IMMX, OCS, SLGL, SRZN, RCKT, GPCR, TARS, VYNE and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.